Restricted Access

Before you enter

All products are sold strictly for in-vitro laboratory research — not for human consumption, therapeutic, or veterinary use.

Your confirmation is saved for 7 days. You will only be asked to confirm once per week.
By entering you accept full responsibility for compliance with all applicable laws.

For research use only  ·  Not for human or animal consumption
Home/Products/Tesamorelin
Tesamorelin research vial Third-party tested
Secretagogue Peptide

Tesamorelin

TH9507
GHRH(1-44) analog CAS 218949-48-5

A 44-amino acid GHRH analog that stimulates pituitary gh secretion, studied for visceral adipose tissue reduction in clinical research.

$100.00$5.00 / mg
Strength

Availability: 6 in stock

Fast U.S. shippingFree on orders over $200
Third-party testedIndependent lab, every batch
Purity documentedHPLC + mass spec
Secure checkoutVenmo · Cash App · Zelle
01Research snapshot

Tesamorelin, by the numbers.

Structural and laboratory facts that define this compound. For laboratory research use only.

0
Amino acid residues

Full-length GHRH(1-44) sequence

0
Molecular weight

g/mol · C221H366N72O67S

0
N-terminal modification

trans-3-hexenoyl group for stability

0%+
Target purity

Reverse-phase HPLC

02Molecular structure

The Tesamorelin molecule

A schematic atomic representation shown next to the compound's molecular data. The figure is illustrative, not a measured conformation.

CHNOS
Molecular formula
C221H366N72O67S
Mol. weight5135.9 g/mol
Sequence length—
CAS218949-48-5
Physical formLyophilized powder
Purity99%+ HPLC
Use classResearch only
03Mechanism of action

How it is studied.

GHRH receptor signaling studied across metabolic, body composition, and cognitive research models

01
GHRH-R Agonism Growth Hormone Secretagogue

Tesamorelin is a synthetic trans-3-hexenoic acid-modified analog of human GHRH(1-44). It binds and activates pituitary GHRH receptors, stimulating endogenous growth hormone (GH) secretion while preserving normal pulsatile GH release patterns — unlike exogenous GH administration.

  • Selective GHRH receptor agonism
  • Preserves pulsatile GH secretion physiology
  • Stimulates downstream IGF-1 production
02
Lipolysis Visceral Adipose Reduction

Clinical evidence demonstrates tesamorelin reduces visceral adipose tissue (VAT) through GH-mediated lipolytic pathways. GH activates hormone-sensitive lipase in adipocytes, promoting free fatty acid release from visceral fat depots. This mechanism underlies its FDA-approved indication for HIV-related lipodystrophy.

  • Stimulates GH-dependent hormone-sensitive lipase activity
  • Selectively targets visceral (not subcutaneous) fat
  • Preserves lean body mass in research models
03
Neuroprotection Cognitive & Brain Research

Emerging research explores tesamorelin's effects on brain structure and function via IGF-1 signaling. Studies in older adults with mild cognitive impairment report changes in regional gray matter volume and functional connectivity. GH/IGF-1 axis modulation is hypothesized to support neuroplasticity mechanisms.

  • Increases circulating IGF-1, which crosses the blood-brain barrier
  • Associated with changes in cortical gray matter volume
  • Under investigation for cognitive aging research models

Research pathway map

The primary pathways Tesamorelin is investigated against in laboratory models.

TesamorelinTARGETS01GHRH-R Agonism02Lipolysis03Neuroprotection
Illustrative schematic based on published in-vitro and preclinical observations. Research use only.
04Specifications

Compound details.

Chemical nameN-(trans-3-hexenoyl)-GHRH(1-44) amide
SynonymsTH9507, GHRH(1-44) analog
FormulaC221H366N72O67S
Molecular weight5135.9 g/mol
CAS number218949-48-5
FormLyophilized powder
DocumentationThird-party COA, per batch

Storage & handling

Supplied as a lyophilized powder. Store the sealed vial refrigerated at 2–8°C, protected from light and moisture; −20°C for long-term storage. Keep reconstituted material refrigerated.

FOR RESEARCH USE ONLYNot for human or animal consumption. Intended strictly for qualified researchers performing in-vitro or analytical laboratory work. No medical, diagnostic or therapeutic claims are made.
Basic Clin Pharmacol Toxicol · 2007Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue

Preclinical pharmacology of TH9507.

Ferdinandi ES et al., 2007 · PubMed ↗
N Engl J Med · 2007Metabolic effects of a growth hormone-releasing factor in patients with HIV

Clinical study of TH9507.

Falutz J et al., 2007 · PubMed ↗
Lancet HIV · 2019Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Clinical study of hepatic fat endpoints.

Stanley TL et al., 2019 · PubMed ↗
0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Scroll to Top